INS and Failure to thrive: In our series, we evaluated the growth status for a median duration of 4 years (oldest patient now 18 years old) and found that the majority of cases have failure to thrive and short stature despite treatment with replacement doses of insulin and pancreatic enzymes (Fig. 2).